Immature platelets were counted by the Sysmex® XE-500 Instrument (Sysmex Corporation, Kobe, Japan); high-sensitivity C-reactive protein (CRP) was measured by an ELISA Kit (Cyclex Co.Ltd, Nagano, Japan), sRAGE by Quantikine® ELISA human RAGE kit (R&D System, Minneapolis, MN), interleukin (IL)-15 by Quantikine® ELISA kit (R&D Systems) and IL-6 by an EIA kit-human (Cayman Europe, Tallinn, Estonia). All measurements were made according to the manufacturer's instructions. For serum thromboxane (TX) B 2 measurements, briefly, 2 ml of venous blood were collected into a glass tube without anticoagulant, immediately clotted for 1 hour at 37° C, centrifuged at 1,200 g for 10 min and the supernatant serum was stored at -20°C until assayed. Serum TXB 2 was measured using an enzyme immunoassay (EIA), as previously described (1; 2). Urinary 11-dehydro-TXB 2 (TXM) and 8iso-PGF 2α were extracted by a chromatographic method adapted to 1 ml of urine, and measured by EIA assays (3; 4). Urinary 2,3-dinor-6-keto-PGF 1α (PGIM) was measured by as previously described by liquid chromatography-tandem mass spectrometry (5). All urinary metabolite measurements were expressed as pg/mg of urinary creatinine, assessed by a colorimetric kit (Creatinine Colorimetric Detection Kit; Enzo Life Sciences, Farmingdale, NY). Triglycerides -mmol/L 0.7 [0.6-1] 0.7 [0.6-1] 0.6 [0.6-1] AST -U/L 17 [13-21] 17 [13-21] 16 [11-20] ALT -U/L 15 [11-19] 15 [12-17] 16 [14-20] eGFR -mL/min 121 ± 28 116 ± 27 112 ± 24 Microalbuminuria -mg/L 7 [3-12] 7 [4-12] NA Platelet Count -10 3 /μL 230 [194-280] 228 [198-286] 263 [211-294] Mean platelet volume
Check of compliance
Compliance was assessed by pill count at the last visit, before witnessed aspirin administration, as well as by comparing serum TXB 2 levels in each patients measured at two time points: immediately before the in-hospital witnessed administration, i.e. at 8 pm of the 20th day on treatment and 24 hours after the witnessed administration. The serum TXB 2 levels measured before the witnessed administration would likely reflect compliance of the patient at home during the previous 3-4 days. This method not only reflects compliance, but might also unmask recent intake of NSAIDs. If the value of serum TXB 2 at 8pm of day 20 differed by >20% from the corresponding value at 8pm on day 21 (postwitnessed) the patient was further investigated and questioned about compliance, time of aspirin intake at home and possible NSAID use. The cutoff of 20% took into account the variability of the serum TXB 2 analytical assay, i.e. ~15%. None of our T1DM or healthy subjects had differences between the two time points > 20%. In particular, we measured the following values of serum TXB 2 in the T1DM cohort: 3.4 [2.3-6.3] ng/ml on day 20 th and 3.5 [2.1-5.5] ng/ml on day 21st (p=0.7 for paired comparisons).
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1. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA: Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Haemost 112:118-127, 2014 Supplementary Figure 1. Consistency of thromboxane biosynthesis over time in T1DM. The figure shows individual urinary TXM excretion values measured in 9 T1DM subjects who were sampled 3 times over 7 to 10 days (visits 1 to 3). Horizontal bars represent the mean value for each visit. Intrapatient values were not significantly different across different visits. Figure 6 . Unchanged F 2 -isoprostane and PGIM biosynthesis in T1DM subjects following aspirin administration. A) Box-whisker plots represent medians and IQR of urinary 8-iso-PGF 2α excretion values measured in 31 T1DM subjects at baseline (pre-aspirin) and between 12 hrs and 7 days after the last witnessed aspirin intake. Values were not-significantly different among the different time-points. B) The box-whisker plots represent medians and IQR of urinary PGIM excretion rates in T1DM subjects (n=31) before starting a three-week course of 100 mg daily aspirin and 24 hrs after the last witnessed intake. Pre-and post-aspirin values were not significantly different.
Supplementary Table 1. Summary of published studies exploring platelet function or platelet-related indexes in T1DM

Study (reference) Population Methodology Results
Alessandrini P et al (N Engl J Med 319:208-212, 1988) 28 TIDM with and without retinopathy, 20 controls Urinary excretion of 2,3-dinor-TXB 2 and 2,3-dinor-6-keto-prostaglandin F 1α , platelet granule constituents, the aggregation response to ADP or arachidonic acid, and levels of serum TXB 2 2,3-dinor-TXB 2 and 2,3-dinor-6-ketoprostaglandin F 1α did not differ between diabetics with or without retinopathy and controls. Platelet granule constituents, the aggregation response to ADP or arachidonic acid and serum TXB 2 failed to discriminate between the groups Hu H et al (Thromb Res 106:91-95, 2002) Platelets isolated from 10 patients and 10 controls Platelets pre-incubated with insulin, Cpeptide or both and then ADPstimulated. Platelet-fibrinogen binding and P-selectin with FACS analysis Insulin pre-incubation did not influence in vitro platelet reactivity (Circulation 107:3199-3203, 2003) Pediatric patients: 23 new-onset T1DM, 23 T1DM > 1 yr, 23 controls Urinary 8-iso-PGF 2α , TXM, plasma IL-6, TNF- , serum CRP.
Davi' G et al
Urinary 8-iso-PGF 2α , TXM, IL-6, CRP and TNF- higher in patients vs. controls. Newlydiagnosed patients had higher prostanoid excretion than patients with established disease. Disease duration and IL-6 predicted 8iso-PGF 2α Yngen M et al (Diabetologia 47:537-540, 2004) T1DM adult patients without (n=19) and with (n=20) microangiopathy; 27 controls Thrombin-induced platelet P-selectin; soluble CD40 ligand and P-selectin, CRP, soluble E-selectin.
All parameters increased only in patients with microangiopathy. No differences between controls and patients without microangiopathy. Values are mean ± SD or median and IQR. None of the differences is statistically significant unless indicated. Abbreviations: CGM: continuous glucose monitoring; TXM: thromboxane metabolite; TX: thromboxane ; 8-iso-PGF 2α : 8-iso-prostaglandinF 2α .
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